BMO Initiates Coverage On This Gene Editing Spearhead

• BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ: NTLA) with a Market Perform rating and a $54 target price.

• The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.

• But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ: EDIT), and high patient compliance remains.

• Related: Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer.

• Although early data suggest that lead asset NTLA-2001 can have a competitive profile in ATTR, penetration will be challenged due to alternative approved/investigational treatments characterized by favorable outcomes and high patient adherence.

• BMO writes that IND approval for NTLA-2001 can drive ~10-15%+ upside in NTLA.

• Price Action: NTLA shares are up 4.17% at $43.17 during the market session on the last check Friday.

Latest Ratings for NTLA

Date	Firm	Action	From	To
Mar 2022	Brookline Capital	Upgrades	Hold	Buy
Mar 2022	Chardan Capital	Maintains		Buy
Feb 2022	William Blair	Initiates Coverage On		Outperform

View More Analyst Ratings for NTLA

View the Latest Analyst Ratings

See more from Benzinga

• BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

• BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.